E-viri
Recenzirano
Odprti dostop
-
Menzies, Nicolas A, Prof; Gomez, Gabriela B, PhD; Bozzani, Fiammetta, MSc; Chatterjee, Susmita, PhD; Foster, Nicola, MPH; Baena, Ines Garcia, MSc; Laurence, Yoko V, MSc; Qiang, Sun, Prof; Siroka, Andrew, PhD; Sweeney, Sedona, MSc; Verguet, Stéphane, PhD; Arinaminpathy, Nimalan, DPhil; Azman, Andrew S, PhD; Bendavid, Eran, MD; Chang, Stewart T, PhD; Cohen, Ted, Prof; Denholm, Justin T, PhD; Dowdy, David W, MD; Eckhoff, Philip A, PhD; Goldhaber-Fiebert, Jeremy D, PhD; Handel, Andreas, PhD; Huynh, Grace H, PhD; Lalli, Marek, MSc; Lin, Hsien-Ho, ScD; Mandal, Sandip, PhD; McBryde, Emma S, PhD; Pandey, Surabhi, PhD; Salomon, Joshua A, Prof; Suen, Sze-chuan, MS; Sumner, Tom, PhD; Trauer, James M, MBBS; Wagner, Bradley G, PhD; Whalen, Christopher C, Prof; Wu, Chieh-Yin, MS; Boccia, Delia, PhD; Chadha, Vineet K, MD; Charalambous, Salome, PhD; Chin, Daniel P, MD; Churchyard, Gavin, Prof; Daniels, Colleen, MA; Dewan, Puneet, MD; Ditiu, Lucica, MD; Eaton, Jeffrey W, PhD; Grant, Alison D, Prof; Hippner, Piotr, MSc; Hosseini, Mehran, MD; Mametja, David, MPH; Pretorius, Carel, PhD; Pillay, Yogan, PhD; Rade, Kiran, MD; Sahu, Suvanand, MD; Wang, Lixia, MS; Houben, Rein M G J, PhD; Kimerling, Michael E, MD; White, Richard G, PhD; Vassall, Anna, PhD
The Lancet global health, 11/2016, Letnik: 4, Številka: 11Journal Article
Summary Background The post-2015 End TB Strategy sets global targets of reducing tuberculosis incidence by 50% and mortality by 75% by 2025. We aimed to assess resource requirements and cost-effectiveness of strategies to achieve these targets in China, India, and South Africa. Methods We examined intervention scenarios developed in consultation with country stakeholders, which scaled up existing interventions to high but feasible coverage by 2025. Nine independent modelling groups collaborated to estimate policy outcomes, and we estimated the cost of each scenario by synthesising service use estimates, empirical cost data, and expert opinion on implementation strategies. We estimated health effects (ie, disability-adjusted life-years averted) and resource implications for 2016–35, including patient-incurred costs. To assess resource requirements and cost-effectiveness, we compared scenarios with a base case representing continued current practice. Findings Incremental tuberculosis service costs differed by scenario and country, and in some cases they more than doubled existing funding needs. In general, expansion of tuberculosis services substantially reduced patient-incurred costs and, in India and China, produced net cost savings for most interventions under a societal perspective. In all three countries, expansion of access to care produced substantial health gains. Compared with current practice and conventional cost-effectiveness thresholds, most intervention approaches seemed highly cost-effective. Interpretation Expansion of tuberculosis services seems cost-effective for high-burden countries and could generate substantial health and economic benefits for patients, although substantial new funding would be required. Further work to determine the optimal intervention mix for each country is necessary. Funding Bill & Melinda Gates Foundation.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.